Yup, Colistin is usually the last defense against MDR Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter. All are Gram-negative bacteria, which CTIX has several promising defensin-mimetic compounds against. In animal studies, CTIX-1807 is potent against E. coli, K. pneumoniae and E. cloacae, including MDR CRE strains. The compound is currently being optimized to expand coverage to Pseudomonas and Acinetobacter. Fingers crossed that CTIX will be successful in doing so.
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links